Related Experiment Video
Updated: May 1, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
CDKN2A unclassified variants in familial malignant melanoma: combining functional and computational approaches for
Maria Chiara Scaini1, Giovanni Minervini, Lisa Elefanti
1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Abstract:
CDKN2A codes for two oncosuppressors by alternative splicing of two first exons: p16INK4a and p14ARF. Germline mutations are found in about 40% of melanoma-prone families, and most of them are missense mutations mainly affecting p16INK4a. A growing number of p16INK4a variants of uncertain significance (VUS) are being identified but, unless their pathogenic role can be demonstrated, they cannot be used for identification of carriers at risk. Predicting the effect of these VUS by either a "standard" in silico approach, or functional tests alone, is rather difficult. Here, we report a protocol for the assessment of any p16INK4a VUS, which combines experimental and computational tools in an integrated approach. We analyzed p16INK4a VUS from melanoma patients as well as variants derived through permutation of conserved p16INK4a amino acids. Variants were expressed in a p16INK4a-null cell line (U2-OS) and tested for their ability to block proliferation. In parallel, these VUS underwent in silico prediction analysis and molecular dynamics simulations. Evaluation of in silico and functional data disclosed a high agreement for 15/16 missense mutations, suggesting that this approach could represent a pilot study for the definition of a protocol applicable to VUS in general, involved in other diseases, as well.
Insights
This study introduces a novel protocol combining computational and experimental methods to assess the impact of p16INK4a variants of uncertain significance (VUS) in melanoma. The integrated approach accurately predicts the pathogenicity of these genetic variants, aiding in risk assessment for hereditary cancer.
Area of Science:
- Genetics and Molecular Biology
- Cancer Research
- Bioinformatics
Background:
- The CDKN2A gene encodes two tumor suppressors, p16INK4a and p14ARF, crucial for cell cycle regulation.
- Germline mutations in CDKN2A are implicated in approximately 40% of melanoma-prone families, predominantly missense mutations affecting p16INK4a.
- Numerous p16INK4a variants of uncertain significance (VUS) hinder accurate genetic risk assessment for melanoma.
Purpose of the Study:
- To develop and validate an integrated protocol for assessing the pathogenicity of p16INK4a VUS.
- To combine in silico prediction tools with experimental functional assays for robust variant interpretation.
- To establish a framework for evaluating VUS in other disease contexts.
Main Methods:
- Expression of p16INK4a VUS in a p16INK4a-null U2-OS cell line to assess proliferation-blocking activity.
- In silico prediction analysis of VUS pathogenicity.
- Molecular dynamics simulations and functional data integration for variant assessment.
Main Results:
- A high degree of agreement (15/16 missense mutations) was observed between in silico predictions and experimental functional data.
- The integrated approach demonstrated efficacy in classifying the functional impact of p16INK4a missense variants.
- The protocol shows promise for the reliable assessment of VUS in hereditary cancer predisposition.
Conclusions:
- The combined computational and experimental protocol provides a reliable method for interpreting p16INK4a VUS.
- This approach can improve the identification of individuals at risk for melanoma due to CDKN2A mutations.
- The developed methodology serves as a foundation for assessing VUS across various genetic disorders.
